| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥65.4B | ¥59.1B | +10.7% |
| Operating Income | ¥3.5B | ¥0.0B | +93.3% |
| Ordinary Income | ¥3.6B | ¥-5.1B | +95.8% |
| Net Income | ¥2.6B | ¥-8.2B | +132.1% |
| ROE | 8.5% | -26.1% | - |
Medical Data Vision Co., Ltd. (MDV) reported FY2025 consolidated results with revenue of 65.4 billion yen (YoY +10.7%), operating income of 3.5 billion yen (YoY +93.3%), ordinary income of 3.6 billion yen (YoY +95.8%), and net income of 2.6 billion yen (YoY +132.1%). The company achieved a significant turnaround from prior year losses, with operating margin improving to approximately 5.3%. The profitability recovery was driven by revenue growth combined with controlled selling, general and administrative expenses, though extraordinary losses of approximately 295 million yen were recorded. Operating cash flow of 782 million yen significantly exceeded net income, representing a conversion ratio of 2.79 times, indicating strong cash-backed earnings quality. Total assets stood at 47.8 billion yen with equity of 31.1 billion yen, maintaining a healthy equity ratio of 65.1%.
Revenue increased 10.7% YoY to 65.4 billion yen, reflecting expansion in the medical data network business. Cost of sales rose 7.8% to 19.9 billion yen, resulting in gross profit of 45.5 billion yen with an improved gross margin of 69.6% compared to 68.8% in the prior year. This 0.8 percentage point margin expansion demonstrates operational efficiency gains in the company's core data services. Selling, general and administrative expenses increased 11.0% to 42.0 billion yen, slightly outpacing revenue growth, yet the absolute operating profit improvement of 3.5 billion yen from break-even prior year indicates successful cost management relative to the revenue base expansion. Operating income of 3.5 billion yen marks a dramatic recovery from virtually zero in the prior year, driven primarily by the combination of higher-margin revenue growth and absorption of fixed costs across a larger revenue base.
At the ordinary income level, non-operating items contributed a net positive of approximately 100 million yen, with financial income offsetting interest expenses. The company recorded extraordinary losses of approximately 295 million yen, which included loss on valuation of investment securities. Despite these non-recurring charges, net income reached 2.6 billion yen compared to a loss of 8.2 billion yen in the prior year, representing a 132.1% improvement. The gap between ordinary income of 3.6 billion yen and net income of 2.6 billion yen reflects the impact of extraordinary losses and tax expenses. Notably, investment securities decreased 66.2% from 438 million yen to 148 million yen on the balance sheet, suggesting portfolio liquidation that may have contributed to valuation-related charges. This represents a revenue up/profit up pattern, with both top-line growth and bottom-line profitability improvement driven by operational leverage and return to core business profitability.
The company operates a single segment in the medical data network business, and therefore segment-by-segment analysis is not applicable.
[Profitability] ROE of 9.0% represents a significant recovery from negative territory in the prior year, calculated through DuPont analysis as net profit margin 4.3% times asset turnover 1.369 times financial leverage 1.54. Operating margin improved to 5.3% from approximately zero YoY, while net profit margin reached 4.0% compared to a loss position previously. The most substantial change was the swing in net profit margin from negative to positive, which served as the primary driver of ROE improvement. Gross profit margin expanded 0.8 percentage points to 69.6%, indicating improved pricing power or cost efficiency in service delivery. [Cash Quality] Operating cash flow of 782 million yen exceeded net income of 264 million yen by 2.79 times, demonstrating strong cash conversion. Cash and deposits increased 27.2% to 1,713 million yen, providing coverage of 1.13 times against short-term liabilities. The accrual ratio of negative 10.5% indicates conservative revenue recognition with cash collection preceding or matching income recognition. [Investment Efficiency] Total asset turnover of 1.369 reflects efficient utilization of the asset base to generate revenue. Capital expenditure to depreciation ratio of 0.75 suggests maintenance-level investment rather than aggressive growth capital deployment. Contract liabilities of 796 million yen on the balance sheet indicate recurring revenue structure with advance payments from customers. [Financial Health] Equity ratio of 65.1% demonstrates a conservative capital structure with low financial risk. Current ratio of 222.2% indicates strong liquidity with current assets of 3,356 million yen covering current liabilities of 1,511 million yen by more than double. Debt-to-equity ratio of 0.54 reflects moderate leverage. Total liabilities decreased slightly to 1,667 million yen, maintaining financial stability.
Operating cash flow of 782 million yen represents 2.79 times net income of 264 million yen, confirming earnings quality through strong cash generation from core operations. The substantial excess of operating cash flow over reported profit suggests working capital benefits or timing differences in accrual versus cash-based accounting. Investing cash flow of 96 million yen consisted primarily of capital expenditures, with the capex-to-depreciation ratio of 0.75 indicating replacement-level rather than expansion-focused investment. The significant decrease in investment securities from 438 million yen to 148 million yen suggests asset liquidation of approximately 290 million yen, which would have contributed to investing cash inflows and supported the overall cash position. Free cash flow of 686 million yen (operating CF minus investing CF) demonstrates robust cash generation capacity. Financing cash flow included share buybacks of 153 million yen and dividend payments, reflecting capital allocation toward shareholder returns. Cash and deposits increased 366 million yen YoY to 1,713 million yen, strengthening the liquidity buffer. The working capital position improved with accounts payable increasing 28.8% to 282 million yen, suggesting effective supplier credit utilization. The combination of strong operating cash flow generation, modest capital investment requirements, and strategic asset portfolio optimization resulted in enhanced cash reserves and financial flexibility to support the high dividend payout and share repurchase program.
Ordinary income of 3.6 billion yen versus operating income of 3.5 billion yen shows a modest net non-operating contribution of approximately 100 million yen, indicating that profitability is predominantly driven by core operations rather than financial or one-time items at the ordinary level. Non-operating income and expenses largely offset each other, with financial income balancing interest expenses. The presence of extraordinary losses of approximately 295 million yen, including loss on valuation of investment securities, represents a material non-recurring factor affecting net income. These extraordinary items account for approximately 0.5% of revenue but represent 11% of ordinary income, highlighting the impact of portfolio management activities on bottom-line results. The sharp reduction in investment securities from 438 million yen to 148 million yen correlates with valuation losses, suggesting portfolio restructuring or mark-to-market adjustments. Operating cash flow of 782 million yen significantly exceeds net income of 264 million yen, with the ratio of 2.79 indicating high-quality earnings backed by actual cash generation. The negative accrual ratio of 10.5% further supports earnings quality, as it demonstrates that cash collection is occurring at a faster pace than revenue recognition, reducing concerns about aggressive accounting. The contract liabilities of 796 million yen represent deferred revenue from customer contracts, typical of subscription or recurring revenue business models, which provides visibility into future revenue recognition. Overall, earnings quality is strong from an operating perspective, with the primary earnings volatility arising from non-recurring investment portfolio adjustments rather than core business performance.
The company declared a year-end dividend of 6.50 yen per share with no interim dividend, resulting in an annual dividend of 6.50 yen per share. Based on net income attributable to owners of parent of 280 million yen and total dividends, the calculated payout ratio is approximately 92.9%, which represents a very high level of earnings distribution to shareholders. The company also executed share buybacks totaling 153 million yen during the period, demonstrating a commitment to total shareholder returns. Combining dividends and share repurchases, the total return ratio significantly exceeds 100% of net income, indicating that shareholder returns are being funded partially from operating cash flow of 782 million yen rather than net income alone. Free cash flow of 686 million yen provides coverage of 2.64 times for dividend payments, suggesting that the cash generation capacity can support the current dividend level despite the elevated payout ratio. The sustainability of this high payout policy depends on the continuation of strong operating cash flow generation and the absence of major valuation losses or extraordinary charges in future periods.
Single segment concentration risk in the medical data network business creates dependency on the healthcare data market, customer contract renewals, and regulatory environment for medical information handling. Any deterioration in customer relationships, budget constraints among healthcare institutions, or loss of major contracts could materially impact revenue stability. Regulatory and data privacy compliance risks are inherent in handling medical data, with potential exposure to changes in personal information protection laws, healthcare data regulations, or compliance failures that could result in operational restrictions or reputational damage. Investment portfolio volatility and valuation risk, as evidenced by the 66.2% reduction in investment securities and recorded valuation losses of approximately 295 million yen in extraordinary items, demonstrates exposure to mark-to-market fluctuations and potential future non-recurring charges that could create earnings volatility beyond core operating performance.
[Industry Position] (Reference - Proprietary Analysis) Medical Data Vision operates in the specialized medical data network services sector. The company's operating margin of 5.3% reflects the current stage of business maturation, having recovered from prior year break-even levels. The 10.7% revenue growth demonstrates market expansion capabilities in the healthcare data analytics space. ROE of 9.0% positions the company at a moderate profitability level following the turnaround from losses, with room for further improvement as operational leverage continues to benefit from revenue scale expansion. The company's historical trend shows operating margin progression to 5.3% in 2025 from lower levels, and net profit margin of 4.0% in 2025 represents a recovery trajectory. Asset turnover of 1.369 indicates relatively efficient asset utilization for a data-services business model. The equity ratio of 65.1% reflects a conservative financial structure compared to typical technology or service companies that may operate with higher leverage. The high dividend payout ratio of 92.9% is notable and suggests a shareholder-friendly capital allocation policy, though sustainability warrants monitoring relative to industry practices and growth investment requirements. Industry comparison is limited due to the specialized nature of medical data network services, but the company's transition from loss to profit with double-digit revenue growth and strong cash generation indicates improving competitive positioning within its niche market.
The company has achieved a significant financial turnaround in FY2025, with operating income recovering to 3.5 billion yen from break-even and net income swinging from an 8.2 billion yen loss to 2.6 billion yen profit, demonstrating successful operational restructuring and core business stabilization. Operating cash flow of 782 million yen exceeding net income by 2.79 times indicates high-quality earnings backed by actual cash generation, providing a solid foundation for the aggressive shareholder return policy of 92.9% dividend payout plus share buybacks totaling 153 million yen. The balance sheet has been strengthened through portfolio optimization, with investment securities reduced 66.2% and cash reserves increased 27.2% to 1,713 million yen, resulting in a current ratio of 222% and improved financial flexibility, though the investment portfolio adjustment resulted in approximately 295 million yen of extraordinary losses that create near-term earnings volatility risk for future periods.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.